Analyst Expectations for Esperion Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Esperion Therapeutics (NASDAQ:ESPR) has received 4 bullish analyst ratings in the last quarter with an average price target of $15.25, indicating a significant upside from the current price of $0.9199. The average price target has risen by 69.44% over the past month, suggesting a positive outlook from analysts on the stock.
November 13, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics has received unanimous bullish ratings from analysts, with a consensus price target of $15.25, which is significantly higher than its current trading price.
The unanimous bullish sentiment from analysts, combined with a substantial increase in the average price target, suggests a strong positive outlook for ESPR. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100